An interventional study of Individualized Energy-Restricted Diet and Moderate-Intensity Walking in Obesity & Overweight, sponsored by Dicle University. Completed at 1 site in Turkey (Türkiye). Open to female participants aged 19 Years to 45 Years. Per ClinicalTrials.gov, last updated 2026-08-21.
Sponsored by Dicle University · Not applicable, Interventional, and Treatment
Among 352 studies in Obesity with a site in Turkey — 72 open to participants now, 90 under way, 16 of them phase 3. Obesity · Turkey.
Among the 352 studies in Obesity with a site in Turkey, this one is the 81st largest by enrollment of the 191 interventional ones that give a count, is one of 59 that started in 2026, is one of 160 with no phase, and was the 320th registered.
11,522 studies on the registry are indexed under Obesity; 2,033 are open to participants now.
Browse Obesity studies →72 of the 352 studies in Obesity with a site in Turkey are open now. Recruiting first, the newest first:
Pamukkale University · Sites in Turkey
Duzce University · Sites in Turkey
Pamukkale University · Sites in Turkey
Kocaeli University · Sites in Turkey
Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkey · Sites in Turkey
A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →
Of the 1,336 Obesity studies recruiting now, 377 (28%) set no upper age limit and 856 (64%) stop at 75 or younger; 168 take children under 18; 491 take healthy volunteers.
This study: 19 Years to 45 Years · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
352 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 2 3 · Phase 3 27 · Phase 4 3
First in 2005; this study’s year is marked. 59 started in 2026.
This study's enrollment of 75 is above the median of 67 across 9,006 interventional studies indexed under Obesity.
Median enrollment 64 across the 191 interventional studies, 82 across the 160 observational. Of the 236 that completed or were terminated, 7 (3%) have results posted.
This tab as a report to print or save as PDF → With an account.
34 of 352 have an industry lead sponsor. The 10 most frequent:
Dicle University is the lead sponsor of 28 studies on the registry; 7 are open to participants now.
Dicle University has 3 studies filed under Obesity — fewer than ten, so there is no comparison to draw.
34 of the studies in Obesity with a site in Turkey that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05556512Phase 3Eli Lilly and CompanyA Study of Tirzepatide (LY3298176) on the Reduction on Morbidity and Mortality in Adults With Obesity | 2027-10 |
| NCT07769736Istinye UniversityMotivational Interviews Based on the Five-Step (5A) Model on Obesity Risk | 2026-11 |
| NCT07652151Fundación Pública Andaluza para la gestión de la Investigación en SevillaUNMASK: Unveiling the Pathobiology of Metabolic Dysfunction-Associated Steatotic Liver Disease for the Discovery of Novel Therapeutics and Biomarkers | 2026-11 |
| NCT07878299Sultan Abdulhamid Han Training and Research Hospital, Istanbul, TurkeyComparison of Segmental Body Composition Characteristics in Lipedema and Obesity | 2026-11-20 |
| NCT07846956Istanbul Saglik Bilimleri UniversityNAION in Non-Diabetic Obese Patients Using GLP-1 Receptor Agonists: A Real-World Study | 2026-11-30 |
Among the 352 studies in Obesity with a site in Turkey, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This randomized controlled study evaluated the effects of diet, exercise, and electrical muscle stimulation (EMS) on body measurements, blood test results, and appetite in women with overweight or obesity.
A total of 75 women aged 19-45 years with a body mass index (BMI) of 25 kg/m² or higher were randomly assigned to one of three groups: diet alone, diet plus exercise, or diet plus EMS. All participants received an individualized energy-restricted diet. Participants in the exercise group also performed at least 30 minutes of moderate-intensity walking daily, while participants in the EMS group received abdominal EMS twice per week for six weeks.
Body measurements, selected biochemical parameters, and appetite-related measures, including hunger, satiety, and desire to eat, were assessed before and after the six-week intervention. The study aimed to determine whether adding exercise or EMS to an individualized energy-restricted diet provides additional benefits for body composition, metabolic health, and appetite regulation in women with overweight or obesity.
This randomized controlled study included 75 women aged 19-45 years with overweight or obesity (BMI ≥25 kg/m²). Eligible participants were randomly assigned to three intervention groups, with 25 participants in each group.
All participants received an individualized energy-restricted dietary program designed to provide an energy deficit of approximately 500 kcal/day. The dietary plans provided approximately 55-60% of total energy from carbohydrates, 12-15% from protein, and 25-30% from fat, with a target dietary fiber intake of 25-30 g/day. Participants attended weekly follow-up visits throughout the intervention.
Participants in the Diet Group received the individualized dietary intervention alone. Participants in the Diet + Exercise Group received the same dietary intervention and were instructed to perform at least 30 minutes of moderate-intensity walking daily throughout the six-week intervention. Participants in the Diet + EMS Group received the dietary intervention together with localized abdominal electrical muscle stimulation. EMS was administered twice weekly on non-consecutive days for six weeks, for a total of 12 sessions. Each EMS session lasted approximately 25 minutes.
Anthropometric assessments included body weight, BMI, waist circumference, hip circumference, neck circumference, mid-upper arm circumference, body fat percentage, fat mass, and fat-free mass. Selected biochemical parameters were assessed using fasting blood samples. Appetite-related outcomes, including hunger, satiety, and desire to eat, were evaluated using a Visual Analog Scale (VAS).
Measurements were obtained at baseline and after completion of the six-week intervention. The primary objective was to compare changes in anthropometric outcomes among the three intervention groups. Additional evaluations examined changes in biochemical parameters and subjective appetite-related outcomes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received an individualized energy-restricted diet program with an energy deficit of approximately 500 kcal/day for 6 weeks.
Behavioral: Individualized Energy-Restricted Diet
Participants received the individualized energy-restricted diet program and were instructed to perform at least 30 minutes of moderate-intensity walking daily throughout the 6-week intervention period.
Behavioral: Individualized Energy-Restricted Diet · Behavioral: Moderate-Intensity Walking
Participants received the individualized energy-restricted diet program in addition to localized abdominal electrical muscle stimulation (EMS). EMS was administered twice weekly on non-consecutive days for 6 weeks, for a total of 12 sessions, with each session lasting approximately 25 minutes.
Behavioral: Individualized Energy-Restricted Diet · Device: Electrical Muscle Stimulation (EMS)
Participants received an individualized energy-restricted diet designed to provide an energy deficit of approximately 500 kcal/day. The diet provided 55-60% of total energy from carbohydrates, 12-15% from protein, and 25-30% from fat, with a target fiber intake of 25-30 g/day. Participants attended weekly follow-up visits throughout the 6-week intervention period.
Participants were instructed to perform at least 30 minutes of moderate-intensity walking daily throughout the 6-week intervention period. Walking intensity was defined as producing a slight increase in heart rate and breathing while allowing participants to maintain conversation comfortably.
Localized abdominal electrical muscle stimulation was administered twice weekly on non-consecutive days for 6 weeks, for a total of 12 sessions. Each session lasted approximately 25 minutes. Four surface electrodes were positioned symmetrically on the abdominal region. Stimulation was delivered at 85 Hz with a pulse width of approximately 300-400 μs, and intensity was increased according to individual tolerance to achieve visible and palpable muscle contractions without pain or discomfort.
Change in Body Weight
Body weight was measured in kilograms using a bioelectrical impedance analysis device (InBody 270) at baseline and after completion of the intervention. Change in body weight was evaluated by comparing the post-intervention measurement with the baseline measurement.
Time frame: Baseline and 6 weeks
Change in Body Mass Index (BMI)
Body mass index (BMI) was calculated as body weight in kilograms divided by height in meters squared (kg/m²) at baseline and after the 6-week intervention.
Time frame: Baseline and 6 weeks
Change in Body Fat Percentage
Body fat percentage was assessed using bioelectrical impedance analysis (InBody 270) at baseline and after the 6-week intervention.
Time frame: Baseline and 6 weeks
Change in Fat Mass
Fat mass was assessed using bioelectrical impedance analysis (InBody 270) at baseline and after the 6-week intervention.
Time frame: Baseline and 6 weeks
Change in Fat-Free Mass
Fat-free mass was assessed using bioelectrical impedance analysis (InBody 270) at baseline and after the 6-week intervention.
Time frame: Baseline and 6 weeks
Change in Fasting Blood Glucose
Fasting blood glucose was assessed using fasting blood samples at baseline and after completion of the 6-week intervention.
Time frame: Baseline and 6 weeks
Change in Glycated Hemoglobin (HbA1c)
HbA1c was assessed at baseline and after completion of the 6-week intervention.
Time frame: Baseline and 6 weeks
Change in Fasting Insulin
Fasting insulin was assessed using fasting blood samples at baseline and after completion of the 6-week intervention.
Time frame: Baseline and 6 weeks
Change in HOMA-IR
HOMA-IR was calculated using fasting glucose and fasting insulin values at baseline and after completion of the 6-week intervention.
Time frame: Baseline and 6 weeks
Change in Total Cholesterol
Total cholesterol was assessed using fasting blood samples at baseline and after completion of the 6-week intervention.
Time frame: Baseline and 6 weeks
Change in LDL Cholesterol (LDL-C)
LDL cholesterol (LDL-C) was assessed using fasting blood samples at baseline and after completion of the 6-week intervention.
Time frame: Baseline and 6 weeks
Change in HDL Cholesterol (HDL-C)
HDL cholesterol (HDL-C) was assessed using fasting blood samples at baseline and after completion of the 6-week intervention.
Time frame: Baseline and 6 weeks
Change in Triglycerides
Triglyceride levels were assessed using fasting blood samples at baseline and after completion of the 6-week intervention.
Time frame: Baseline and 6 weeks
Change in Aspartate Aminotransferase (AST)
Aspartate aminotransferase (AST) levels were assessed using fasting blood samples at baseline and after completion of the 6-week intervention.
Time frame: Baseline and 6 weeks
Change in Alanine Aminotransferase (ALT)
Alanine aminotransferase (ALT) levels were assessed using fasting blood samples at baseline and after completion of the 6-week intervention.
Time frame: Baseline and 6 weeks
Change in C-Reactive Protein (CRP)
C-reactive protein (CRP) levels were assessed using fasting blood samples at baseline and after completion of the 6-week intervention.
Time frame: Baseline and 6 weeks
Change in Blood Urea Nitrogen (BUN)
Blood urea nitrogen (BUN) levels were assessed using fasting blood samples at baseline and after completion of the 6-week intervention.
Time frame: Baseline and 6 weeks
Change in Serum Creatinine
Serum creatinine was assessed using fasting blood samples at baseline and after completion of the 6-week intervention.
Time frame: Baseline and 6 weeks
Change in Serum Iron
Serum iron was assessed using fasting blood samples at baseline and after completion of the 6-week intervention.
Time frame: Baseline and 6 weeks
Change in Vitamin B12
Serum vitamin B12 was assessed using fasting blood samples at baseline and after completion of the 6-week intervention.
Time frame: Baseline and 6 weeks
Change in 25-Hydroxyvitamin D [25(OH)D]
Serum 25(OH)D was assessed using fasting blood samples at baseline and after completion of the 6-week intervention.
Time frame: Baseline and 6 weeks
Change in Thyroid-Stimulating Hormone (TSH)
TSH was assessed using fasting blood samples at baseline and after completion of the 6-week intervention.
Time frame: Baseline and 6 weeks
Change in Appetite-Related Visual Analog Scale Scores
Hunger, satiety, and desire to eat were assessed using a 100-mm Visual Analog Scale (VAS) at baseline and after the 6-week intervention. Higher scores indicated greater intensity of the respective appetite sensation. Changes in hunger, satiety, and desire-to-eat scores were evaluated between baseline and post-intervention measurements.
Time frame: Baseline and 6 weeks
Plan to share: Yes — upon reasonable request
No publications or documents are linked to this record.
Ran from Jan 2026 to primary completion in Mar 2026, 2 months.
Of 3,680 non-industry interventional studies with no phase under Obesity, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's 2 months is below that.
Counting every sponsor, half of 3,843 studies reached it within 22 months; a quarter within 10 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Dicle University